IO Biotech, Inc.
IOBT
$0.64
$0.011.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.27% | 14.65% | 5.49% | -9.62% | 8.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.97% | 7.60% | 11.82% | -4.40% | 12.86% |
| Operating Income | 26.97% | -7.60% | -11.82% | 4.40% | -12.86% |
| Income Before Tax | 57.82% | -28.49% | -16.98% | -19.59% | -7.63% |
| Income Tax Expenses | -896.17% | -68.45% | -64.82% | 26.06% | 147.61% |
| Earnings from Continuing Operations | 65.11% | -26.74% | -15.23% | -19.67% | -10.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.11% | -26.74% | -15.23% | -19.67% | -10.78% |
| EBIT | 26.97% | -7.60% | -11.82% | 4.40% | -12.86% |
| EBITDA | 27.03% | -7.63% | -11.86% | 4.43% | -12.86% |
| EPS Basic | 65.65% | -26.72% | -15.24% | -19.68% | 15.64% |
| Normalized Basic EPS | 58.46% | -28.49% | -17.00% | -19.59% | 18.04% |
| EPS Diluted | 65.65% | -26.72% | -15.24% | -19.68% | 15.64% |
| Normalized Diluted EPS | 58.46% | -28.49% | -17.00% | -19.59% | 18.04% |
| Average Basic Shares Outstanding | 1.61% | 0.00% | 0.00% | 0.00% | 31.32% |
| Average Diluted Shares Outstanding | 1.61% | 0.00% | 0.00% | 0.00% | 31.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |